

Latest Articles


FLUNITY-HD
The FLUNITY-HD Study is the largest individually randomized influenza vaccine effectiveness study and the first of its kind for an influenza vaccine. The study demonstrates the superior benefit of HD-IIV, specifically developed for older adults, compared with SD-IIV against a wide range of hospitalization outcomes in a prespecified and powered analysis encompassing nearly half a million participants. Providing the high-quality data, this study provides further critical evidence that widespread use of HD-IIV could substantially reduce the burden of influenza on both older adults and healthcare systems globally.
Real-World Effectiveness of Nirsevimab: Evidence from the NIRSE-GAL Study
The NIRSE-GAL study is an ongoing population-based, prospective, longitudinal study conducted in Galicia, Spain. It includes infants eligible to receive nirsevimab and evaluates its impact on RSV-related outcomes in both inpatient and outpatient healthcare settings.
Healthcare Resource Utilization and Direct Medical Costs of RSV Infection in Children Under Five Years in Saudi Arabia
An overview of the latest Saudi evidence presented at ESPID 2026.
Epidemiology and Healthcare Burden Attributable to Laboratory-Confirmed RSV Cases Among Children Under Five Years Old in Saudi Arabia
An overview of the latest Saudi evidence presented at ESPID 2026.
Expanding RSV Protection in Kuwait: New National Directives for Monoclonal Antibody Use
Summary of Kuwait’s updated RSV prevention policy
Evidence on Nirsevimab: Sustained Impact Across Two RSV Seasons
Drawing on data NirseGAL, this page provides healthcare professionals with evidence-based insights into nirsevimab's sustained protective impact across two consecutive RSV seasons
IL-4/IL-13 Dual Cytokine Signaling in Severe Asthma: Mechanistic Insights by Prof. Kenneth Chapman
Recognizing the key cytokines driving type 2 inflammation and understanding their profound impact on patients’ asthma burden is crucial.1-3